1. Hepatocyte cholesterol content modulates glucagon receptor signalling
- Author
-
Emma Rose McGlone, T. Bertie Ansell, Cecilia Dunsterville, Wanling Song, David Carling, Alejandra Tomas, Stephen R. Bloom, Mark S.P. Sansom, Tricia Tan, and Ben Jones
- Subjects
Glucagon ,Glucagon receptor ,Cholesterol ,Cell membrane ,Non-alcoholic fatty liver disease ,Type 2 diabetes mellitus ,Internal medicine ,RC31-1245 - Abstract
Structured abstract: Objective: To determine whether glucagon receptor (GCGR) actions are modulated by cellular cholesterol levels. Methods: We determined the effects of experimental cholesterol depletion and loading on glucagon-mediated cAMP production, ligand internalisation and glucose production in human hepatoma cells, mouse and human hepatocytes. GCGR interactions with lipid bilayers were explored using coarse-grained molecular dynamic simulations. Glucagon responsiveness was measured in mice fed a high cholesterol diet with or without simvastatin to modulate hepatocyte cholesterol content. Results: GCGR cAMP signalling was reduced by higher cholesterol levels across different cellular models. Ex vivo glucagon-induced glucose output from mouse hepatocytes was enhanced by simvastatin treatment. Mice fed a high cholesterol diet had increased hepatic cholesterol and a blunted hyperglycaemic response to glucagon, both of which were partially reversed by simvastatin. Simulations identified likely membrane-exposed cholesterol binding sites on the GCGR, including a site where cholesterol is a putative negative allosteric modulator. Conclusions: Our results indicate that cellular cholesterol content influences glucagon sensitivity and indicate a potential molecular basis for this phenomenon. This could be relevant to the pathogenesis of non-alcoholic fatty liver disease, which is associated with both hepatic cholesterol accumulation and glucagon resistance.
- Published
- 2022
- Full Text
- View/download PDF